Cargando…

干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595861/
https://www.ncbi.nlm.nih.gov/pubmed/33113610
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.09.011
_version_ 1783601974084632576
collection PubMed
description
format Online
Article
Text
id pubmed-7595861
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-75958612020-10-30 干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2020-09 /pmc/articles/PMC7595861/ /pubmed/33113610 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.09.011 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察
title 干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察
title_full 干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察
title_fullStr 干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察
title_full_unstemmed 干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察
title_short 干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察
title_sort 干扰素α-1b、白细胞介素-2联合沙利度胺方案维持治疗急性髓系白血病的临床观察
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595861/
https://www.ncbi.nlm.nih.gov/pubmed/33113610
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.09.011
work_keys_str_mv AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá
AT gànrǎosùa1bbáixìbāojièsù2liánhéshālìdùànfāngànwéichízhìliáojíxìngsuǐxìbáixuèbìngdelínchuángguānchá